HISA Issues Updated Withdrawal Guidance For Phenylbutazone

Sarah Andrew Photo

The Anti-Doping and Medication Control (ADMC) program has proposed enforcing the screening limit of phenylbutazone at 300 ng/mL in blood, rather than the previously established screening limit of 200 ng/mL in blood. HISA will file Guidance with the Federal Trade Commission that will implement this change in the enforcement of the screening limit. The RMTC's Scientific Advisory Committee (SAC) has been asked by industry stakeholders to review its withdrawal guidance of phenylbutazone based upon the updated proposed screening limit. Based on the updated screening limit of 300 ng/mL in blood and a single IV dose of 4.4 mg/kg, the SAC has reviewed all available data and is now recommending an updated withdrawal guidance of 72 hours for phenylbutazone. The RMTC's Withdrawal Guidance of HISA's ADMC Detection Times document will reflect those changes.

Not a subscriber? Click here to sign up for the daily PDF or alerts.

Copy Article Link

Liked this article? Read more like this.

  1. Both Sides in Pending Eighth Circuit HISA Case Attempt to Spin Conflicting Opinions from Two Other Appeals Courts
  2. David O'Rourke Joins TDN Writers' Room Podcast To Talk Saratoga
  3. Part of HISA Ruled Unconstitutional in Fifth Circuit Decision
  4. Nevada Litfin Suspended Five Years for Recruiting 'Paper Trainer' While Sanctioned
  5. Stewards and Commissions Rulings, June 27 – July 3

Never miss another story from the TDN

Click Here to sign up for a free subscription.